Pluri (FRA:4DX) Valuation Rank


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €16.85
! 6 Warning Signs
View Full Analysis

What is Pluri Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pluri Valuation Rank Related Terms

FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 66.8% below its estimated GF Value™ of €16.85.

Key valuation signals for FRA:4DX:

  • Valuation Rank:
  • GF Value™: €16.85 vs. price of €5.60 (66.8% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€16.85
GF Value